Rovia Clinical Research, a multi-specialty, clinical research site network, on Thursday announced the launch of a new, dedicated clinical research site at the Hattiesburg Clinic (HBC) in Hattiesburg, Mississippi, in partnership with principal investigator Dr. Rambod Rouhbakhsh.
HBC, a privately-owned, multi-specialty health system in Mississippi, accommodates more than 450 physicians and providers and serves patients across 17 counties with around 2,000 staff members.
This collaboration extends Rovia's footprint into Mississippi and aims to improve its capabilities in key therapeutic areas while reinforcing a shared, patient-centric mission to advance clinical research.
"The Hattiesburg Clinic and Dr. Rouhbakhsh are highly respected in the region and nation, and we are thrilled to partner with them to launch this new site in an underserved, major geographic region," commented Rovia CEO Patricio Casillas.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA